Zenas Biopharma Inc (ZBIO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 38.99 is considered Undervalued compared with the five-year average of -4.40. The fair price of Zenas Biopharma Inc (ZBIO) is between 62.43 to 104.84 according to relative valuation method. Compared to the current price of 25.56 USD , Zenas Biopharma Inc By Undervalued By 59.06%.

Relative Value

Fair Zone

62.43-104.84

Current Price：25.56

59.06%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Zenas Biopharma Inc (ZBIO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Zenas Biopharma Inc (ZBIO) has a current Price-to-Book (P/B) ratio of 7.41. Compared to its 3-year average P/B ratio of 2.65, the current P/B ratio is approximately 179.89% higher. Relative to its 5-year average P/B ratio of 2.65, the current P/B ratio is about 179.89% higher. Zenas Biopharma Inc (ZBIO) has a Forward Free Cash Flow (FCF) yield of approximately -8.56%. Compared to its 3-year average FCF yield of -21.90%, the current FCF yield is approximately -60.91% lower. Relative to its 5-year average FCF yield of -21.90%, the current FCF yield is about -60.91% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ZBIO competitors is 374.74, providing a benchmark for relative valuation. Zenas Biopharma Inc Corp (ZBIO.O) exhibits a P/S ratio of 38.99, which is -89.6% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ZBIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ZBIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ZBIO currently overvalued or undervalued?

What is Zenas Biopharma Inc (ZBIO) fair value?

ZBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Zenas Biopharma Inc (ZBIO) is between 62.43 to 104.84 according to relative valuation method.

How does ZBIO's valuation metrics compare to the industry average?

The average P/S ratio for ZBIO's competitors is 374.74, providing a benchmark for relative valuation. Zenas Biopharma Inc Corp (ZBIO) exhibits a P/S ratio of 38.99, which is -89.60% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Zenas Biopharma Inc (ZBIO) as of Mar 03 2026?

As of Mar 03 2026, Zenas Biopharma Inc (ZBIO) has a P/B ratio of 7.41. This indicates that the market values ZBIO at 7.41 times its book value.

What is the current FCF Yield for Zenas Biopharma Inc (ZBIO) as of Mar 03 2026?

As of Mar 03 2026, Zenas Biopharma Inc (ZBIO) has a FCF Yield of -8.56%. This means that for every dollar of Zenas Biopharma Inc's market capitalization, the company generates -8.56 cents in free cash flow.

What is the current Forward P/E ratio for Zenas Biopharma Inc (ZBIO) as of Mar 03 2026?

As of Mar 03 2026, Zenas Biopharma Inc (ZBIO) has a Forward P/E ratio of -10.60. This means the market is willing to pay $-10.60 for every dollar of Zenas Biopharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Zenas Biopharma Inc (ZBIO) as of Mar 03 2026?

As of Mar 03 2026, Zenas Biopharma Inc (ZBIO) has a Forward P/S ratio of 38.99. This means the market is valuing ZBIO at $38.99 for every dollar of expected revenue over the next 12 months.

ZBIO Valuation